Corporate Profile - ds- Corporate Philosophy Corporate Profile Aiming Future Focus Research Areas We

  • View
    0

  • Download
    0

Embed Size (px)

Text of Corporate Profile - ds- Corporate Philosophy Corporate Profile Aiming Future Focus Research Areas We

  • Corporate Profile  

  • Innovation today, healthier tomorrows The global slogan with our full commitment The global slogan reflects our full commitment to deliver to society revolutionary pharmaceuticals, acquired through groundbreaking ideas and high-standard research and development by each individual employee’ s challenge for innovation, so as to help enable the patients and their families lead healthier and fulfilling lives.

    A Message from the President Corporate Philosophy Corporate Profile Corporate History Business Units Aiming Future

  • My name is Hiroshi Nomura, and I have the honor of serving as Representative Director, President and CEO of Sumitomo Dainippon Pharma Co., Ltd.

    The single most important responsibility that I have been given is to ensure the sustainable growth of our company into the future. As such, I will make the most efficient use of all resources available to us, unite our individual strengths, and leverage our wealth of experience so that we can successfully take on this challenge. At the same time, I hope to meet the expectations of all stakeholders in our endeavors to attain this overriding goal.

    Sumitomo Dainippon Pharma Co., Ltd., operates every day to achieve its corporate mission “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.” By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and valuable pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission.

    We will remain committed to research and development by taking every available opportunity to assimilate cutting-edge technologies through combinations of a wide variety of avenues, including in-house research, technology in-licensing, and joint research with academia and biotech companies, with the aim of continually discovering excellent pharmaceutical products in our focus research areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy. Furthermore, we will explore new businesses in the healthcare sector and offer solutions other than treatment by pharmaceutical products in order to gain opportunities to contribute to the well-being of people through the use of digital technologies and other methods.

    Through these undertakings, we will aim to become a “global specialized player” whose presence is felt throughout the world in specific therapeutic areas.

    To fulfill our social responsibilities as a corporation, we not only strengthen our corporate governance system and thoroughly ensure compliance but also take wide-ranging initiatives that include social contribution activities in and outside Japan, promotion of diversity and inclusion, and active communication with diverse stakeholders.

    Always aware of our responsibility to all of our stakeholders, including patients, their families, medical caregivers, our shareholders, employees, and the communities in which we work, we promise to give our most dedicated efforts to earn and maintain your trust in us.

    On behalf of all of us at Sumitomo Dainippon Pharma, I would like to sincerely thank you for your continued support and encouragement.

    Hiroshi Nomura Representative Director, President and CEO Sumitomo Dainippon Pharma Co., Ltd.

    A Message from the President

    A Message from the President Corporate Philosophy Corporate Profile Corporate History Business Units Aiming Future

  • To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide

    ●To contribute to healthcare and people’ s well-being based upon the principles of patient-oriented management and innovative research

    ● To continuously strive to maximize corporate value through constant business development and to fulfill shareholder expectations

    ●To create an environment in which employees can fulfill their potential and increase their creativity ●To maintain the trust of society and to contribute to the realization of a better global environment

    At Sumitomo Dainippon Pharma, directors and employees alike are determined not only to comply with all laws and regulations, but also to ensure that all corporate activities are carried out in accordance with this Declaration of Conduct. The pledges below express our commitment to earning greater trust from society and becoming a truly innovative company.

    1. Follow through the global slogan “Innovation today, healthier tomorrows.”

    2. Pursue trustworthy corporate activities.

    3. Positively disclose information and properly manage information.

    4. Help employees reach their full potential.

    5. Respect human rights.

    6. Positively address global environmental issues.

    7. Build harmonious relationships with society.

    Corporate Mission

    Management Mission

    Declaration of Conduct

    Management Mission

    Declaration of Conduct

    A Message from the President Corporate Philosophy Corporate Profile

    Corporate Philosophy

    Corporate Mission

    Corporate History Business Units Aiming Future

  • Name Sumitomo Dainippon Pharma Co., Ltd.

    Establishment May 14, 1897 Date of merger October 1, 2005 Capitalization 22.4 billion yen Employees 3,067(6,140 : consolidated)(as of March 31, 2019)

    Key Facilities 〈Head Offices〉 Osaka Head Office, Tokyo Head Office 〈Branches〉 15 Branches 〈Plants〉 Suzuka Plant, Oita Plant 〈Research Laboratories〉 Central Research Laboratories, Osaka Research Center 〈Distribution Center〉 Kobe Distribution Center, Tokyo Distribution Center

    Business(consolidated) Manufacturing and sales of pharmaceuticals, food ingredients, food additives, veterinary medicines and others

    Osaka Head Office 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, 541-0045, Japan Tokyo Head Office 13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, 104-8356, Japan

    Business Results(Year ended March 31, 2019) Revenue(459.3 billion yen) Core operating profit(77.3 billion yen) R&D expenses(82.9 billion yen)

    Segment Revenue

    North America  55.0 %Japan

    28.2 %

    Other Business 8.3 % |

    Other Regions 3.1 %

    China 5.4 %

    A Message from the President Corporate Philosophy Corporate Profile

    Corporate Profile

    Corporate History Business Units Aiming Future

  • A Message from the President Corporate Philosophy Corporate Profile

    Corporate History

    Sumitomo Dainippon Pharma created on October 1, 2005. 2009 ● Acquired Sepracor Inc., a U.S. company (current Sunovion Pharmaceuticals Inc.). 2012 ●

    Acquired Boston Biomedical, Inc., a U.S. company. Sunovion Pharmaceuticals Inc. acquired Elevation Pharmaceuticals, Inc., a U.S. company (current Sunovion Respiratory Development Inc.)

    2013 ● ●

    A subsidiary (Sunovion Pharmaceuticals Asia Pacific Pte. Ltd.) established in Singapore. An anti-cancer drugs sales subsidiary company (Boston Biomedical Pharma, Inc) established in the U.S.

    2014 ● Joint venture company (Sighregen Co., Ltd.) established. 2016 ● Sunovion Pharmaceuticals Inc. acquired Cynapsus Therapeutics Inc., a Canadian company (current Sunovion CNS

    Development Canada ULC).

    2017 ● Acquired Tolero Pharmaceuticals, Inc., a U.S. company. 2018 ● Manufacturing Plant for Regenerative Medicine & Cell Therapy (SMaRT) completed. 2019 ●

    ● Consolidation of production sites. (Reorganized four plants to two plants) With the signing of a strategic alliance agreement with Roivant Sciences, a U.S. subsidiary Sumitovant Biopharma was established to hold shares of Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences.

    Dainippon Pharmaceutical

    1897 ● Dainippon Pharmaceutical Co., Ltd., established on May 14.

    Twenty-one prominent leaders in the pharmaceutical industry in Doshomachi, Osaka, founded Osaka Pharmaceuticals Co., Ltd.

    1898

    ● Pharmaceutical Plant (former Osaka Plant and former Osaka Center) established in Ebie, Osaka. The company acquired the semi-governmental Dainippon Pharmaceutical Company in Tokyo and changed the name of the company to Dainippon Pharmaceutical Co., Ltd.

    Sumitomo Pharmaceuticals

    1984

    ● Sumitomo Pharmaceuticals Co., Ltd., established on February 6, 1984, from the Research, Development, and Manufacturing divisions of Sumitomo Chemical Co., Ltd.’ s pharmaceuticals business, as well as the Pharmaceuticals Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company’ s pharmaceuticals. The new company opened for business on October 1.

    Corporate History Business Units Aiming Future

  • A Message from the President Corporate Philosophy Corporate Profile

    Business Units

    In addition to the Psychiatry & Neurology area, we are focusing on Diabetes and Specialty areas (an area with high unmet medical needs in which intensive specialization is required).

    Number of employees Sumitomo Dainippon Pharma: 3,067 (As of March 31, 2019)

    Main Products TRERIEF® Revenue 15.7 billion yen (FY2018) Launch March 2009

    Indications Parkinson’ s disease,